Description
The LpMab-23 monoclonal antibody specifically recognizes a cancer-specific form of human podoplanin. Podoplanin is a 38-44 kDa type I transmembrane glycoprotein that is encoded by PDPN. This heavily glycosylated mucin type protein is named for its expression on kidney glomerular epithelial cells known as podocytes. Although the podoplanin protein is expressed on a wide variety of cell types in normal tissues (including placenta, lung, skeletal muscle and brain), LpMab-23 recognizes an altered glycosylation pattern that occurs on oral cancer cells and it shows minimal reactivity with the surrounding non-cancerous tissue. In contrast, the LpMab-17 monoclonal antibody recognizes a non-glycosylated epitope of podoplanin on normal and cancer cells. Podoplanin induces platelet aggregation via its three platelet aggregation-stimulating (PLAG) domains; it binds C-type lectin domain family 1 member B (Clec1B, also known as CLEC2); and it is involved in actin cytoskeleton organization and in cellular adhesion and migration. It also plays roles in organogenesis, vascular development, inflammatory diseases, tumorigenesis, and cancer cell motility and metastasis.
For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime two or more BD Horizon Brilliant dyes (including BD OptiBuild Brilliant reagents) are used in the same experiment. Fluorescent dye interactions may cause staining artifacts which may affect data interpretation. The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794).
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated with BD Horizon BUV563 under optimal conditions that minimize unconjugated dye and antibody.
1. This antibody was developed for use in flow cytometry.
2. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
3. Researchers should determine the optimal concentration of this reagent for their individual applications.
4. An isotype control should be used at the same concentration as the antibody of interest.
5. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
6. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
7. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
8. BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
